Positive News SentimentPositive NewsNASDAQ:FGEN FibroGen (FGEN) Stock Price, News & Analysis $7.45 +0.22 (+3.04%) Closing price 07/25/2025 03:59 PM EasternExtended Trading$7.44 -0.01 (-0.13%) As of 07/25/2025 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About FibroGen Stock (NASDAQ:FGEN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get FibroGen alerts:Sign Up Key Stats Today's Range$7.04▼$7.5650-Day Range$5.16▼$8.6152-Week Range$4.50▼$33.00Volume23,252 shsAverage Volume47,293 shsMarket Capitalization$30.10 millionP/E RatioN/ADividend YieldN/APrice Target$250.00Consensus RatingModerate Buy Company Overview FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California. Read More FibroGen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks92nd Percentile Overall ScoreFGEN MarketRank™: FibroGen scored higher than 92% of companies evaluated by MarketBeat, and ranked 86th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingFibroGen has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageFibroGen has only been the subject of 1 research reports in the past 90 days.Read more about FibroGen's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for FibroGen are expected to grow in the coming year, from ($0.80) to ($0.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of FibroGen is -2.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of FibroGen is -2.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about FibroGen's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.56% of the float of FibroGen has been sold short.Short Interest Ratio / Days to CoverFibroGen has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in FibroGen has recently decreased by 11.00%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldFibroGen does not currently pay a dividend.Dividend GrowthFibroGen does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.84 Percentage of Shares Shorted4.56% of the float of FibroGen has been sold short.Short Interest Ratio / Days to CoverFibroGen has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in FibroGen has recently decreased by 11.00%, indicating that investor sentiment is improving significantly. News and Social Media2.7 / 5News SentimentN/A News SentimentFibroGen has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.07 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for FibroGen this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for FGEN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, FibroGen insiders have bought more of their company's stock than they have sold. Specifically, they have bought $119,485.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.07% of the stock of FibroGen is held by insiders.Percentage Held by Institutions72.71% of the stock of FibroGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about FibroGen's insider trading history. Receive FGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for FibroGen and its competitors with MarketBeat's FREE daily newsletter. Email Address FGEN Stock News HeadlinesFibroGen, Inc (NASDAQ:FGEN) Director James A. Schoeneck Acquires 23,567 SharesJuly 3, 2025 | insidertrades.comFibroGen Inc.June 24, 2025 | marketwatch.com[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…July 26 at 2:00 AM | GoldCo Precious Metals (Ad)FibroGen To Implement 1-for-25 Reverse Stock SplitJune 14, 2025 | nasdaq.comFibroGen, Inc. Announces 1-for-25 Reverse Stock Split Effective June 16, 2025June 14, 2025 | nasdaq.comFibroGen Enters Relicensing Agreement with HiFiBiOJune 13, 2025 | marketwatch.comFibroGen Announces 1-for-25 Reverse Stock SplitJune 12, 2025 | globenewswire.comFibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of DirectorsJune 9, 2025 | globenewswire.comSee More Headlines FGEN Stock Analysis - Frequently Asked Questions How have FGEN shares performed this year? FibroGen's stock was trading at $13.2375 at the beginning of 2025. Since then, FGEN stock has decreased by 43.7% and is now trading at $7.45. How were FibroGen's earnings last quarter? FibroGen, Inc (NASDAQ:FGEN) issued its quarterly earnings results on Monday, May, 12th. The biopharmaceutical company reported ($4.00) earnings per share for the quarter, missing the consensus estimate of $0.75 by $4.75. The biopharmaceutical company earned $2.70 million during the quarter, compared to analysts' expectations of $2 million. Read the conference call transcript. When did FibroGen's stock split? FibroGen's stock reverse split on the morning of Tuesday, June 17th 2025.The 1-25 reverse split was announced on Thursday, June 12th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 16th 2025. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did FibroGen IPO? FibroGen (FGEN) raised $146 million in an initial public offering on Friday, November 14th 2014. The company issued 8,100,000 shares at $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners served as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers. How do I buy shares of FibroGen? Shares of FGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of FibroGen own? Based on aggregate information from My MarketBeat watchlists, some other companies that FibroGen investors own include Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), Voyager Therapeutics (VYGR), The RMR Group (RMR), iShares Micro-Cap ETF (IWC) and AU Optronics (AUOTY). Company Calendar Last Earnings5/12/2025Today7/25/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:FGEN CIK921299 Webwww.fibrogen.com Phone(415) 978-1200Fax415-978-1902Employees570Year FoundedN/APrice Target and Rating Average Price Target for FibroGen$250.00 High Price Target$250.00 Low Price Target$250.00 Potential Upside/Downside+3,255.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($2.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$47.58 million Net Margins-9.73% Pretax Margin-117.74% Return on EquityN/A Return on Assets-24.77% Debt Debt-to-Equity RatioN/A Current Ratio2.02 Quick Ratio1.98 Sales & Book Value Annual Sales$29.62 million Price / Sales1.02 Cash FlowN/A Price / Cash FlowN/A Book Value($50.89) per share Price / Book-0.15Miscellaneous Outstanding Shares4,040,000Free Float3,918,000Market Cap$30.10 million OptionableOptionable Beta0.74 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:FGEN) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FibroGen, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share FibroGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.